169 related articles for article (PubMed ID: 19602237)
1. RIZ1 is potential CML tumor suppressor that is down-regulated during disease progression.
Lakshmikuttyamma A; Takahashi N; Pastural E; Torlakovic E; Amin HM; Garcia-Manero G; Voralia M; Czader M; DeCoteau JF; Geyer CR
J Hematol Oncol; 2009 Jul; 2():28. PubMed ID: 19602237
[TBL] [Abstract][Full Text] [Related]
2. RIZ1 repression is associated with insulin-like growth factor-1 signaling activation in chronic myeloid leukemia cell lines.
Pastural E; Takahashi N; Dong WF; Bainbridge M; Hull A; Pearson D; Huang S; Lowsky R; DeCoteau JF; Geyer CR
Oncogene; 2007 Mar; 26(11):1586-94. PubMed ID: 16953217
[TBL] [Abstract][Full Text] [Related]
3. Activation of EVI1 transcription by the LEF1/β-catenin complex with p53-alteration in myeloid blast crisis of chronic myeloid leukemia.
Manachai N; Saito Y; Nakahata S; Bahirvani AG; Osato M; Morishita K
Biochem Biophys Res Commun; 2017 Jan; 482(4):994-1000. PubMed ID: 27908728
[TBL] [Abstract][Full Text] [Related]
4. miR-96 acts as a tumor suppressor via targeting the BCR-ABL1 oncogene in chronic myeloid leukemia blastic transformation.
Huang T; Fu Y; Wang S; Xu M; Yin X; Zhou M; Wang X; Chen C
Biomed Pharmacother; 2019 Nov; 119():109413. PubMed ID: 31518872
[TBL] [Abstract][Full Text] [Related]
5. Gadd45a deficiency accelerates BCR-ABL driven chronic myelogenous leukemia.
Mukherjee K; Sha X; Magimaidas A; Maifrede S; Skorski T; Bhatia R; Hoffman B; Liebermann DA
Oncotarget; 2017 Feb; 8(7):10809-10821. PubMed ID: 28086219
[TBL] [Abstract][Full Text] [Related]
6. [Down-regulation of transcription factor PU.1 via abnormal epigenetic modification in chronic myeloid leukemia].
Yang H; Yan JS; Tao R; Hao SG; Liang H; Ma LY
Zhonghua Zhong Liu Za Zhi; 2012 Mar; 34(3):169-75. PubMed ID: 22780968
[TBL] [Abstract][Full Text] [Related]
7. [Molecular analysis of transformation into blast crisis in chronic myelogenous leukemia].
Okabe M
Hokkaido Igaku Zasshi; 1993 Mar; 68(2):237-50. PubMed ID: 8509066
[TBL] [Abstract][Full Text] [Related]
8. A deletion polymorphism in the RIZ gene is associated with increased progression of imatinib treated chronic myeloid leukemia patients.
Mir R; Najar IA; Guru S; Javaid J; Yadav P; Masroor M; Zuberi M; Farooq S; Bhat M; Gupta N; Ray PC; Saxena A
Leuk Lymphoma; 2017 Jul; 58(7):1694-1701. PubMed ID: 27830966
[TBL] [Abstract][Full Text] [Related]
9. Identification of novel posttranscriptional targets of the BCR/ABL oncoprotein by ribonomics: requirement of E2F3 for BCR/ABL leukemogenesis.
Eiring AM; Neviani P; Santhanam R; Oaks JJ; Chang JS; Notari M; Willis W; Gambacorti-Passerini C; Volinia S; Marcucci G; Caligiuri MA; Leone GW; Perrotti D
Blood; 2008 Jan; 111(2):816-28. PubMed ID: 17925491
[TBL] [Abstract][Full Text] [Related]
10. Enhanced expression of p210BCR/ABL and aberrant expression of Zfp423/ZNF423 induce blast crisis of chronic myelogenous leukemia.
Miyazaki K; Yamasaki N; Oda H; Kuwata T; Kanno Y; Miyazaki M; Komeno Y; Kitaura J; Honda Z; Warming S; Jenkins NA; Copeland NG; Kitamura T; Nakamura T; Honda H
Blood; 2009 May; 113(19):4702-10. PubMed ID: 19234145
[TBL] [Abstract][Full Text] [Related]
11. Induced dendritic cell differentiation of chronic myeloid leukemia blasts is associated with down-regulation of BCR-ABL.
Lindner I; Kharfan-Dabaja MA; Ayala E; Kolonias D; Carlson LM; Beazer-Barclay Y; Scherf U; Hnatyszyn JH; Lee KP
J Immunol; 2003 Aug; 171(4):1780-91. PubMed ID: 12902478
[TBL] [Abstract][Full Text] [Related]
12. Cadherin-13 in primary and blast crisis chronic myeloid leukaemia: declining expression and negative correlation with the BCR/ABL fusion gene.
Mu HJ; Xie R; Shen YF; Jiang YQ; Zeng YJ
Br J Biomed Sci; 2009; 66(1):20-4. PubMed ID: 19348122
[TBL] [Abstract][Full Text] [Related]
13. Acquired loss of p53 induces blastic transformation in p210(bcr/abl)-expressing hematopoietic cells: a transgenic study for blast crisis of human CML.
Honda H; Ushijima T; Wakazono K; Oda H; Tanaka Y; Aizawa Si; Ishikawa T; Yazaki Y; Hirai H
Blood; 2000 Feb; 95(4):1144-50. PubMed ID: 10666183
[TBL] [Abstract][Full Text] [Related]
14. Regulation of myeloid leukaemia by the cell-fate determinant Musashi.
Ito T; Kwon HY; Zimdahl B; Congdon KL; Blum J; Lento WE; Zhao C; Lagoo A; Gerrard G; Foroni L; Goldman J; Goh H; Kim SH; Kim DW; Chuah C; Oehler VG; Radich JP; Jordan CT; Reya T
Nature; 2010 Aug; 466(7307):765-8. PubMed ID: 20639863
[TBL] [Abstract][Full Text] [Related]
15. The expression pattern of erythrocyte/megakaryocyte-related transcription factors GATA-1 and the stem cell leukemia gene correlates with hematopoietic differentiation and is associated with outcome of acute myeloid leukemia.
Shimamoto T; Ohyashiki K; Ohyashiki JH; Kawakubo K; Fujimura T; Iwama H; Nakazawa S; Toyama K
Blood; 1995 Oct; 86(8):3173-80. PubMed ID: 7579412
[TBL] [Abstract][Full Text] [Related]
16. Bcr-Abl induces autocrine IGF-1 signaling.
Lakshmikuttyamma A; Pastural E; Takahashi N; Sawada K; Sheridan DP; DeCoteau JF; Geyer CR
Oncogene; 2008 Jun; 27(27):3831-44. PubMed ID: 18246120
[TBL] [Abstract][Full Text] [Related]
17. Increase of bcr-abl chimeric mRNA expression in tumor cells of patients with chronic myeloid leukemia precedes disease progression.
Gaiger A; Henn T; Hörth E; Geissler K; Mitterbauer G; Maier-Dobersberger T; Greinix H; Mannhalter C; Haas OA; Lechner K; Lion T
Blood; 1995 Sep; 86(6):2371-8. PubMed ID: 7662984
[TBL] [Abstract][Full Text] [Related]
18. Expression of the miR-17-92 polycistron in chronic myeloid leukemia (CML) CD34+ cells.
Venturini L; Battmer K; Castoldi M; Schultheis B; Hochhaus A; Muckenthaler MU; Ganser A; Eder M; Scherr M
Blood; 2007 May; 109(10):4399-405. PubMed ID: 17284533
[TBL] [Abstract][Full Text] [Related]
19. The tumor suppressor PP2A is functionally inactivated in blast crisis CML through the inhibitory activity of the BCR/ABL-regulated SET protein.
Neviani P; Santhanam R; Trotta R; Notari M; Blaser BW; Liu S; Mao H; Chang JS; Galietta A; Uttam A; Roy DC; Valtieri M; Bruner-Klisovic R; Caligiuri MA; Bloomfield CD; Marcucci G; Perrotti D
Cancer Cell; 2005 Nov; 8(5):355-68. PubMed ID: 16286244
[TBL] [Abstract][Full Text] [Related]
20. FTY720, a new alternative for treating blast crisis chronic myelogenous leukemia and Philadelphia chromosome-positive acute lymphocytic leukemia.
Neviani P; Santhanam R; Oaks JJ; Eiring AM; Notari M; Blaser BW; Liu S; Trotta R; Muthusamy N; Gambacorti-Passerini C; Druker BJ; Cortes J; Marcucci G; Chen CS; Verrills NM; Roy DC; Caligiuri MA; Bloomfield CD; Byrd JC; Perrotti D
J Clin Invest; 2007 Sep; 117(9):2408-21. PubMed ID: 17717597
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
